Introduction A drug combination that has gained recent attention for an additive risk of nephrotoxicity is vancomycin plus piperacillin-tazobactam. Clinicians need to better understand whether tubular cell stress occurs with piperacillin-tazobactam administration to establish whether renal injury associated with this combination is a valid clinical concern. Objective An evaluation of the pharmacokinetics of urinary tissue inhibitor of metalloproteinase-2 (TIMP-2) and insulinlike growth factor binding-protein 7 (IGFBP7) for patients receiving vancomycin alone, piperacillin-tazobactam alone, and vancomycin plus piperacillin-tazobactam in combination was conducted to understand the impact on acute kidney cell stress and compare the rates of dialysis or death at 9 months among these three drug exposure types. Methods A secondary analysis of the prospective, multicenter Sapphire study (ClinicalTrials.gov identifier NCT01209169) including 35 intensive care units (ICUs) in North America and Europe was performed. Critically ill adult patients at risk for acute kidney injury (AKI) were included. Urinary [TIMP-2]•[IGFBP7] was measured serially. Patients who received vancomycin alone, piperacillin-tazobactam alone, or vancomycin plus piperacillin-tazobactam were grouped according to their maximum AKI stage within 3 days of the first drug dose. Results Of 723 critically ill adults admitted to the ICU, 46% received either piperacillin-tazobactam (n = 110), vancomycin (n = 156), or both (n = 67). The urinary [TIMP-2]•[IGFBP7] was highest on day 1 for the combination group. AKI stage 2/3 occurred more frequently in patients receiving the drug combination than in those receiving piperacillin-tazobactam alone (p = 0.03) but not vancomycin alone (p = 0.29). Risk of death or dialysis at 9 months was greatest for vancomycin plus piperacillin-tazobactam (48%) and similar for patients receiving vancomycin alone (29%) or piperacillin-tazobactam alone (35%) (p = 0.03 for unadjusted and p = 0.048 after adjusting for covariates). Conclusion After exposure to piperacillin-tazobactam and vancomycin in combination, there was a greater release of AKI biomarkers in patients who develop AKI than with piperacillin-tazobactam or vancomycin monotherapy and the combination is associated with possible increased long-term adverse outcomes. 
Introduction
The risk of drug-induced nephrotoxicity increases with concomitant drug exposure [1] . A drug combination that has gained recent attention for an additive risk of nephrotoxicity is vancomycin plus piperacillin-tazobactam [2, 3] . In critically ill patients, vancomycin plus piperacillin-tazobactam has demonstrated up to a ten times greater odds of developing AKI than vancomycin plus other β-lactam combinations [2] .
Vancomycin-associated acute kidney injury (AKI) occurs in up to 43% of patients [4] . Historically, vancomycin toxicity was attributed to impurities; however, following improvements in product development, AKI is now predominantly associated with increased drug dosages and higher trough concentrations which are surrogate markers for vancomycin area under the concentration-time curve (AUC), and thus there is a current movement towards monitoring vancomycin AUC for efficacy and toxicity [5, 6] . More recently, obstructive cast nephropathy has been proposed as a mechanism of vancomycin-induced nephrotoxicity [5] .
Piperacillin-tazobactam and other β-lactam antibacterials are thought to have similar associations with the development of AKI mediated by acute interstitial nephritis [3] . In one study, the incidence of AKI for piperacillin-tazobactam and ampicillin-sulbactam was 9.5% and 8.9%, respectively; however, with the addition of vancomycin the incidence of AKI increased to 18% for piperacillin-tazobactam and remained stable at 10% for ampicillin-sulbactam [3] . There are multiple studies supporting a significant rise in serum creatinine (SCr) following administration of vancomycin plus piperacillin-tazobactam, so the concern regarding tubular damage and parenchymal injury appears real [2, 3] . An absolute increase in the incidence of AKI was 18% for vancomycin plus piperacillin-tazobactam administered in combination compared with vancomycin or piperacillin-tazobactam monotherapy [7] . It is suggested that there is a pharmacodynamic interaction with the drug combination augmenting the sensitivity associated with piperacillin-tazobactam-related interstitial nephritis and the direct cellular necrosis linked to vancomycin [8.9] . However, a contrary opinion has been postulated, whereby piperacillin-tazobactam competitively inhibits the organic anion transport system preventing the tubular secretion of creatinine, which may elevate SCr and falsely signal AKI with no actual deterioration in renal function or contribution to parenchymal injury (i.e., pseudonephrotoxicity) [10] . Thus, we need to better understand whether tubular cell stress occurs with piperacillin-tazobactam administration to establish whether renal injury associated with this combination is a valid clinical concern.
Urinary tissue inhibitor of metalloproteinase-2 (TIMP-2) and insulin-like growth factor binding-protein 7 (IGFBP7) are cell-cycle arrest biomarkers identifying renal tubular epithelial cell stress [11] . The product of the two substances is the only biomarker laboratory test approved by the Food and Drug Administration (FDA) in the USA to assess the risk of developing moderate to severe AKI. Renal biomarkers are being utilized to better understand the association between tubular cell stress and kidney damage for drug-associated events [12] . Previously, Ostermann and colleagues [13] 
Materials and Methods

Study Design
This is a secondary analysis of the prospective, multicenter Sapphire study (ClinicalTrials.gov identifier NCT01209169 [18] ) of critically ill patients at risk for AKI [11] . The Sapphire study enrolled adult patients admitted to 35 intensive care units (ICUs) in North America and Europe between September 2010 and June 2012. The methods for the Sapphire study have been described previously [11] . In brief, patients with cardiovascular or respiratory dysfunction who were expected to be in the ICU for at least 48 h were enrolled and evaluated for AKI biomarkers.
Sample and Data Collection
As indicated by Ostermann et al. [13] , following informed consent, urine samples were taken at enrollment, twice daily (approximately every 12 h) for 4 days, and then daily (approximately every 24 h) for 3 additional days [11, 13] . Urine supernatants were frozen within approximately 1 h of collection, stored at − 70 °C or lower, and thawed immediately before analysis.
Outcome Assessment
Patients who received piperacillin-tazobactam alone, vancomycin alone, or piperacillin-tazobactam and vancomycin in combination were grouped according to their maximum AKI stage within 3 days of first drug administration. AKI was defined according to the full Kidney Disease Improving Global Outcome (KDIGO) criteria, including both changes in SCr and urine output [14] . The median daily urinary [TIMP-2]•[IGFBP7] was calculated from the day prior to first drug dose (pre-exposure), on the day of first drug exposure (initial exposure), and daily until 5 days after the drug exposure for those patients with an available [TIMP-2]•[IGFBP7], so the same patients were not necessarily included for every timepoint. All clinical outcome data were documented by each site and for each patient, consistent with the study protocol [7] . Mortality and the occurrence of dialysis or death up to 9 months after enrollment were analyzed as per the parent study. Statistical analyses were performed using R version 3.4.4. Two-sided p values < 0.05 and one-sided p values < 0.025 were considered statistically significant.
Statistical Analysis
Results
Of 723 critically ill adults admitted to the ICU, 333 (46%) received either piperacillin-tazobactam (n = 110), vancomycin (n = 156), or both (n = 67). There were 63% males and the median (IQR) age was 65 (54-74) years old. Sex Fig. 2 . Risk of death or dialysis at 9 months was greatest for piperacillin-tazobactam plus vancomycin compared with vancomycin alone (48%; p = 0.03 for unadjusted and p = 0.048 after adjusting for covariates) but similar for patients receiving only vancomycin (29%) or piperacillin-tazobactam (35%).
Discussion
The contribution of piperacillin-tazobactam to renal parenchymal injury in patients receiving piperacillin-tazobactam plus vancomycin has been called into question with the suggestion of pseudonephrotoxicity. This analysis provides support for the theory that kidney stress from this drug combination is present, as exemplified by elevated urinary has been associated with increased rates of death, dialysis, and persistent renal dysfunction [15] . Additionally, patients who received the combination of piperacillin-tazobactam plus vancomycin had a higher incidence of AKI stage 2/3 than piperacillin-tazobactam alone, and poorer 9-month outcomes than vancomycin alone. Collectively, this shows that piperacillin-tazobactam plus vancomycin is associated with both short-and long-term adverse consequences. It also reaffirms that exposure to piperacillin-tazobactam alone increases urinary [TIMP-2]•[IGFBP7] on day 1, which contributes to the underappreciated nephrotoxicity of piperacillin-tazobactam and confirms that a rise in SCr is not merely a 'laboratory abnormality'. for evaluation of renal parenchymal stress/injury but this notion of sequential measurements might be applicable to other kidney biomarkers as well.
Limitations
This study did not control for indication bias; still, all patients did receive antibacterials for a critical illness. This is a post hoc analysis of existing data so cause and effect between antibacterial and AKI is not definitive. Also, it is a convenient sample of limited size, but it is a first step to suggest that kidney stress is real from administration of the piperacillin-tazobactam plus vancomycin combination. These data mimic real-world data when it is not typically feasible to get a biomarker test before antibacterial administration, as shown in ESM 4. Day 3 after exposure All p values were adjusted for multiple comparisons by the Holm's method. AKI acute kidney injury, APACHE Acute Physiology and Chronic Health Evaluation, PIP-TAZO piperacillin-tazobactam was evaluated for AKI, but longer exposure could contribute to AKI progression. While the focus of this paper was not to determine predictors of AKI, including severity of illness, there is some debate over the association between APACHE II and APACHE III with AKI [16, 17] .
Conclusion
Urinary pharmacokinetics of •[IGFBP7] show evidence of kidney stress after exposure to piperacillin-tazobactam, vancomycin, and piperacillin-tazobactam plus vancomycin for patients that progress to stage 2-3 AKI, and the clinical outcomes for the drug combination are concerning.
Compliance with Ethical Standards
Funding The Sapphire study was funded by Astute Medical, Inc. and they supported this secondary evaluation through resources for statistical analysis.
Conflict of interest Sandra Kane-Gill, Marlies Ostermann, and Emily Joyce have no conflicts of interest that are directly relevant to the content of this study. Jing Shi has received consulting fees from Astute Medical, Inc. John Kellum has received grant support and consulting fees from Astute Medica, including licensing fees paid to the University of Pittsburgh by Astute Medical for unrelated technology.
Ethical approval
The Sapphire study was approved by the Western Institutional Review Board (Olympia, WA, USA) and individual review boards or ethics committees as required by each study site.
Informed consent All subjects or authorized representatives provided written informed consent.
